Amicus Therapeutics Inc., of Cranbury, N.J., said that the National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies Evaluation Committee has issued a positive final evaluation determination for reimbursed patient access to Galafold (migalastat). NICE has recommended the commissioning of the drug for use within the National Health Service in England as a first line therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. The company expects to launch Galafold in England, Wales and Northern Ireland early this year.